For over a century, the University of Oregon (UO) has provided students with innovative academic programs. The large, main campus is located in Eugene, and other sites are available in Portland and Charleston (Oregon Institute of Marine Biology). The school even has the Pine Mountain Observatory in Central Oregon, operated by astronomers and UO physics students. UO’s academics offer hundreds of undergraduate and graduate degree programs including: Biochemistry, Business Administration, Interior Architecture, Marine Biology, and Music Education. It even has pre-professional programs in Clinical Laboratory Science, Occupational Therapy, Social Work, Teacher Education, and Veterinary Medicine. Study abroad programs for academic credit are available as well. Admissions materials for the school can be submitted online along with the required application fee. Applications are evaluated based on academic potential, grades, standardized test scores, extracurricular activities, and other considerations. Financial aid is awarded to those who qualify to assist with tuition costs and other educational expenses. Tuition fees are discounted for Oregon residents. College life at UO is full of opportunities: Greek Life, student-run clubs and organizations, recreational activities, sports, and more. The school is also well known for its athletic teams, the Oregon Ducks, who compete in the PAC-12. The football team in particular has built a large fan base, and students can be found at the stadium every home game Saturday during the season. For exceptional academics in a traditional university setting located near the natural beauty of the Pacific Northwest, take a look at the University of Oregon.
BioSuperior is a preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue. They have bio-engineered a novel synthetic pulmonary surfactant prototype, BioSurf, an essential biomaterial required for breathing and having direct therapeutic effects that will be used to deliver potent drugs that restore normal lung function.
NovoClade is a synthetic biology company focused on developing environmentally friendly solutions for insect control and invasive species eradication. The company utilizes gene-editing technology to create sterile mosquito populations, aiming to mitigate the spread of diseases carried by these insects. By offering chemical-free pest control alternatives, NovoClade provides clients with innovative formulas that effectively reduce disease transmission without harming the environment. Through their advancements in genetic bio-control, NovoClade addresses critical public health challenges while promoting sustainable practices in pest management.
Aqua Science offers a global platform of technologies and fast and reliable solutions for the testing and treatment of water. They provide research and development, custom reagent and kit manufacture, product assembly, lyophilization services, and contract manufacturing services.
Ezrabio is a biotechnology company that specializes in RNA adenylation technology, facilitating ribosome profiling across diverse biological samples. By offering rapid cDNA library construction and streamlined services from sample preparation to deep sequencing, Ezrabio empowers researchers and medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and inform mRNA therapeutics. Their innovative approach simplifies complex processes, making it easier for scientists to conduct critical research in genetics and molecular biology.
Iaso Therapeutics develops vaccines to improve human health and cure diseases. The company was founded in 2018 and is based in East Lansing, Michigan.
Auctus Biologics is a pre-clinical biotechnology company focused on developing antibody mimetics for therapeutic and diagnostic uses. By engineering a ribose-binding protein, the company aims to create a scaffold that binds clinical targets with an affinity comparable to monoclonal antibodies while addressing the limitations associated with traditional antibodies. These limitations include instability and the need for costly cold-chain logistics, which can hinder their effectiveness in extreme environments such as the gastrointestinal tract. Auctus Biologics' innovative approach allows for treatments that are not only more resilient, capable of withstanding conditions like repeated boiling cycles, but also more accessible and cost-effective for patients. This advancement may significantly enhance the delivery of advanced medical therapies.
MBF Therapeutics, Inc. is a clinical-stage veterinary oncology company dedicated to developing innovative therapies for dogs and cats with cancer. The company's portfolio includes targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing normal healthy cells. Notable products in development include MBFT-101, a combination therapy for sarcomas and lymphoma that merges a polyamine transport inhibitor with a potent enzyme inhibitor, and MBFT-102, an immunotherapy based on the tumor suppressor mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics is exploring gene-based immunotherapeutic vaccines, aiming to revolutionize cancer treatment and infectious disease prevention in companion animals and livestock. The company collaborates with the Lankenau Institute for Medical Research and is headquartered in Ambler, Pennsylvania.
Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia creates engineered organisms that can be controlled with small molecules.
Spekciton Biosciences specializes in biophotonic measurement systems and services aimed at enhancing agricultural performance and sustainability. The company develops innovative technologies that enable the rapid and precise detection of plant stress and viability, providing farmers with essential insights for improving crop management. Additionally, Spekciton offers biosensors designed to quickly identify soil and water contamination, supporting environmental health and agricultural productivity. Through its advanced measurement solutions, the company contributes to a better understanding of bioprocesses, ultimately aiding in the cultivation of resilient and sustainable crops.
BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.
Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.
Biochip Labs, founded in 2019 and headquartered in Cleveland, Ohio, specializes in laboratory testing services for blood disorders, particularly sickle cell disease and thalassemia. The company offers a variety of proprietary microfluidic biomarker assays that assess blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the efficacy of emerging targeted and curative therapies, allowing clinicians to effectively monitor patient responses to treatment. By focusing on accurate and high-quality testing, Biochip Labs aims to advance the understanding and management of blood disorders.
Frontier Bio Corporation is a biotechnology company based in Oakland, California, that specializes in the development and manufacturing of advanced bioprinting technologies. Founded in 2018, the company has created a unique bioprinter known as FLUX-1, which integrates traditional bioprinting methods with electro-hydrodynamic printing. This innovative approach allows for the precise printing of biological materials at the micro and nanoscale while preserving high cell viability. The FLUX-1 bioprinter is utilized for a range of applications, including the fabrication of tissues such as skin, cartilage, and bone, as well as for drug toxicity testing, tissue implants, drug screening, disease modeling, and the production of prosthetics. Frontier Bio's technology represents a significant advancement in the field of bioprinting, offering new possibilities for medical and research applications.
Biko Biolabs is a research company founded in 2020 and located in Somerville, Massachusetts, that focuses on the intersection of plastic waste and regenerative agriculture. The company aims to address research and development gaps related to sustainability and self-sufficiency in traditionally marginalized communities. By providing resources to innovators, Biko Biolabs fosters the creation of new economic opportunities and trains emerging local scientists and engineers. The company emphasizes impactful research that is closely aligned with the specific needs of the communities involved, enabling tailored scientific practices and technologies that directly address fundamental community challenges.
Developer of virus-resistant live bacterial products designed to modulate the human microbiome. The company targets the viral components of the gut microbiome to treat disease and focus on healthy gut bacteria and their predatory phages to engineer resistant strains, and also develops a new class of live biotherapeutics, enabling medical science professionals to specifically target phages or viruses with a specific affinity for inducing lysis.
Frugi Biotechnology is a synthetic biology company based in Ames, Iowa, founded in 2020. The company specializes in developing modular, paper-based diagnostics aimed at managing viral outbreaks. Frugi's services include creating custom cell-free extracts that facilitate the building and testing of learn cycles for clients involved in protein biomanufacturing and protein discovery. This allows clients to detect pathogens in a simplified and cost-effective manner, enhancing the capabilities for outbreak management and response.
Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.
BioSense8 develops biosensors for use in human and animal healthcare, and environmental wellness. The company was founded in 2020 and is headquartered in Boston, Massachusetts.
Developer of recombinant protein-based materials designed to mimic those naturally found in this environment. The company's products have core protein biometrics composed of a simple modular design, translated into a system that forms fractal-like porous networks with material properties after injection and exposure to body heat, enabling medical researchers to get the required bio-compatible materials used in tissue engineering and regenerative medicine.
Operator of a life science platform intended for democratizing advanced single-cell assays. The company's novel nano vial platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, enabling biotech labs and clients to develop higher-performing therapies for cancer, autoimmune conditions, and infectious diseases.
Lisa Health is a digital platform for menopause and midlife women's health. Menopause is a transition every woman around the globe will experience. Eighty-five percent will have symptoms that adversely impact their health, quality of life, relationships, and productivity at work. Lisa Health manages the menopause journey and midlife wellbeing with personalized, science-based, community-supported guidance.
Fireline Science, founded in 2019 and based in Tempe, Arizona, focuses on developing educational technology products that promote innovation. The company's offerings leverage artificial intelligence and data science to support the creation of digital products and services. Fireline Science aims to address the challenges of digital learning, particularly for students in rural areas with limited internet access or those facing other barriers to connectivity. By providing near-term assistance, the company seeks to enhance educational opportunities and accessibility for all learners.
CellDrop Biosciences, established in 2017 and based in Laramie, Wyoming, specializes in hydrogel-based technology for point-of-care diagnostics and targeted biomaterial delivery. The company focuses on developing hydrogel platforms that enable precise control over chemical and biological systems. Its innovations aim to facilitate the healing of equine musculoskeletal injuries efficiently, while also minimizing the risk of re-injury. By providing effective diagnostic and treatment solutions, CellDrop Biosciences addresses critical needs within the veterinary medical community.
Developer of life science platform intended to provide accurate methods to test dangerous endotoxins. The company provides advanced healthcare innovations for the detection of blood-borne pathogens, enabling physicians to develop a rapid and sensitive diagnostic for detecting bloodstream infection.
Sears Scientific specializes in developing innovative scientific equipment designed to enhance the usability and accessibility of tools used in research. By streamlining processes in fields such as microscopy and vacuum sciences, the company enables researchers to concentrate more on scientific discovery rather than the complexities of their instrumentation. Through its focus on improving the ease-of-use of scientific technologies, Sears Scientific aims to facilitate advancements in research and support the scientific community.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
VeriSIM Life, Inc. develops disease-specific biosimulation models that allow researchers at pharmaceutical companies to model in software how a drug will interact in animals. The company was incorporated in 2017 and is based in San Francisco, California.
CasTag Biosciences specializes in cell biology and regenerative medicine, focusing on revolutionizing the speed of endogenously protein analysis. The company aims to accelerate scientific discovery by offering tools that allow scientists to study novel genes in any experimental model.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.
Creative BioTherapeutics is a biotechnology company developing therapies for cancer and viruses. The company is changing the way that cancer and viral disease research is conducted. It focuses on the root cause of cancer affecting immune evasion and drug resistance.
SKROOT Laboratory specializes in the development of wireless sensor systems designed for biotherapeutic process developers. The company has created a unique sensor sticker that, when applied to a reactor and paired with a reader, provides a wireless, non-invasive platform capable of continuously measuring critical parameters such as cell concentration, foaming, and temperature in upstream cell vessels and single-use bioreactors. This innovative technology enables operators to closely monitor bioprocesses, significantly reducing the risk of advancing costly conditions and accelerating the time to market for biotherapeutic products.
Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.
Ionica Sciences™ is utilizing a new technology platform to meet urgent needs in clinical diagnostics.The ability to rapidly and accurately identify the presence of diseases would provide clinicians with the ability to reduce suffering of their patients, the use of antibiotics, and healthcare costs that result from mis- or missed diagnoses.
FloBio specializes in point-of-care diagnostics focused on assessing bleeding risk through real-time blood analysis. Founded in 2017 and based in Philadelphia, PA, the company has developed an innovative fluidic-based diagnostic platform that utilizes microfluidic technology. This platform allows for rapid and precise measurements of blood clotting function under physiological conditions, enabling clinicians to make informed decisions and personalize patient management swiftly during critical situations.
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.
Ascribe Bioscience develops products that enable farmers to combat crop pathogens without negative impacts on the environment. The company is currently developing a seed treatment product that acts by boosting crops’ natural defenses.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Inherent Biosciences is a molecular diagnostics company that revolutionizes trial and error medicine and restore hope. The company does this by discovering what's inherent in our biology about the unexplained and translating discoveries into personal insights that inform actions. Inherent Biosciences develops medicines for treating pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, COVID-19, and many more.
Developer of high-brightness fluorophores designed to improve the reagents that run through flow cytometers. The company's fluorophores are compatible with current flow cytometers and increase the brightness of fluorophores across the visible range with minimal or no noise distortion, enabling users to detect targeted or cancer cells feasibly.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.
New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.
Gaskiya Diagnostics, founded in 2019 and based in Baltimore, Maryland, specializes in developing paper-based diagnostic test kits for the detection of aquatic diseases. The company employs bioengineered capture proteins to bind to specific disease targets, offering a diagnostic solution that is both cost-effective and easy to use. These tests enable aquaculture farmers to accurately identify and prevent diseases, thereby minimizing potential revenue losses associated with disease outbreaks. Gaskiya's focus on sensitivity and specificity in its diagnostic tools positions it as a valuable partner in the aquaculture industry.
Stemloop is a biotechnology company founded in 2019 and based in Evanston, Illinois. It focuses on developing cell-free biosensing products aimed at revolutionizing chemical and molecular testing. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates simple and cost-effective solutions for the accurate and scalable detection of various chemicals. This innovation enables medical professionals to deliver better and faster test results while reducing costs, thereby enhancing the overall efficiency of testing processes in healthcare and related fields.
Cellulose Sciences International develops novel methods for utilizing celluloses and lignocellulosic. The headquarters of the company are in Madison, Wisconsin.
Operator of a direct-from-blood testing platform designed to identify bloodstream microbes within minutes. The company's platform incorporates a fluidics component that isolates whole pathogens and creates a passage through channels that lyse blood cells, enabling physicians and clinical researchers to eliminate the need to identify bloodstream bacterial disease and get detailed information on all strains of microbes.
Infecho Scientific specializes in instrumentation research and development. The company was founded in May 2017 and is headquartered in Columbia, Missouri.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Koliber Biosciences focuses on advancing biomedical discoveries through a synthetic biology research platform that leverages machine learning and artificial intelligence. The company offers data science services, including the development of predictive models and practical statistics coaching for clients. By specializing in statistically-guided experimental design, modeling, and data analytics, Koliber Biosciences enables pharmaceutical companies to expedite the drug development process, making it more efficient and effective.
Inso Biosciences is an early-stage biotechnology company based in Ithaca, New York, affiliated with Cornell University. The company focuses on developing innovative platform technology for biological sample processing, specifically designed for genomic analysis, including DNA sequencing. Utilizing advanced microfluidic technology, Inso Biosciences aims to revolutionize sample processing by efficiently separating and isolating cellular components. This technology enables healthcare and biotechnology companies to enhance their biological sample preparation capabilities, facilitating more effective research and analysis in the field of genomics.
Provider of end-to-end molecular surveillance services intended to treat infectious disease dynamics and molecular surveillance of pathogens. The company's services include ribonucleic acid (RNA) and deoxyribonucleic acid (RNA) extraction, genomic sequencing, data analytics, and cloud-based data visualizations., enabling clients to research and develop various tests and avail of proper lab services.
LEAH Laboratories specializes in developing innovative gene-editing technologies aimed at treating cancer in dogs, particularly B-cell lymphoma. The company utilizes precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR), creating CAR T cells that can specifically target and eliminate cancerous cells while minimizing off-target effects commonly associated with traditional chemotherapy. By harnessing the natural capabilities of the canine immune system, LEAH Laboratories provides a novel approach to cancer treatment, offering hope to pet owners and veterinarians in their fight against this challenging disease. Based in the United States, LEAH Labs is committed to advancing medical therapies for canine health.
Safebiosense develops biosensing and imaging systems to address a variety of difficult issues in endotoxin detection. The company was founded in 2019 and is headquartered in The Woodlands, Texas.
BioLum Sciences LLC develops and manufactures an asthma management device that allows patients to measure airway inflammation and help patients and doctors keep track of an individual’s health. The device along with an application keeps track of airway condition, track symptoms, measure the efficacy of medications, and share daily measurements with doctor. BioLum Sciences LLC was founded in 2015 and is based in Dallas, Texas.
BioAmp Diagnostics, Inc. is a biotechnology company based in Berkeley, California, founded in 2017. The company focuses on developing precision diagnostic tools aimed at combating antibiotic resistance. By leveraging a patented platform amplification technology, BioAmp creates clinical tests that deliver actionable results, enabling healthcare providers to prescribe the most effective antibiotics for their patients from the outset. This innovative approach not only empowers physicians with critical information but also seeks to improve patient outcomes and promote responsible antibiotic use in the medical community.
Nexilico, Inc. is an early-stage biotechnology company focused on advancing precision medicine through microbiome research and development. Founded in 2017 and based in Berkeley, California, Nexilico specializes in predictive and computational platforms that enhance drug design and development, as well as therapeutics clinical outcomes. The company aims to deepen scientific understanding of microbiomes and their impact on health and disease, utilizing this knowledge to create innovative microbiome-based technologies. By providing solutions that improve therapeutic efficacy, Nexilico positions itself as a key player in the evolving landscape of precision medicine.
HelioBioSys is a biotechnology company that specializes in marine cyanobacteria. The company uses marine cyanobacteria that grow on air, seawater, and sunlight. They produce a variety of complex biopolymers. HelioBioSys has developed cost-effective ways to harvest and process them into concentrated polysaccharides and hydrogels. These sustainably-derived biomaterials have applications in cosmetics, sunscreens and bioplastics.
Envivo Bio develops a non-invasive device that collects microbiome samples from all regions of the human gastrointestinal tract. The company is based in San Carlos, California.
Inso Biosciences is an early-stage biotechnology company based in Ithaca, New York, affiliated with Cornell University. The company focuses on developing innovative platform technology for biological sample processing, specifically designed for genomic analysis, including DNA sequencing. Utilizing advanced microfluidic technology, Inso Biosciences aims to revolutionize sample processing by efficiently separating and isolating cellular components. This technology enables healthcare and biotechnology companies to enhance their biological sample preparation capabilities, facilitating more effective research and analysis in the field of genomics.
Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.
VivoZ Biolabs is a biotechnology company focused on developing and commercializing innovative microfluidic technologies aimed at personalized medicine and drug discovery. The company's flagship product is a patented layered microfluidic tissue assay that closely mimics the dynamic three-dimensional tumor microenvironment. This platform allows for the maintenance of micro-tumor growth and functions ex vivo, facilitating mid-to-high throughput drug screening and diagnosis. By utilizing this technology, healthcare professionals can better predict and select candidate compounds during the drug discovery process, ultimately enhancing personalized cancer treatment options.
Allied Microbiota, LLC is a biotechnology company focused on developing microbial products and enzymes to address environmental contamination more efficiently and cost-effectively than traditional remediation methods. Originating from technology at Columbia University, the company's flagship product, PacBac, offers a microbial-based solution for the rapid reduction of stubborn soil contaminants, including poly-chlorinated biphenyls (PCBs), achieving up to 80% reduction in just days. This innovative approach presents significant cost savings—up to 80% compared to conventional remediation techniques like incineration—while effectively eliminating contaminants as a liability rather than merely relocating them. In addition to PacBac, Allied Microbiota is engaged in ongoing research and development to identify new microbial strains and create additional bio-products using advanced methodologies in synthetic biology, proteomics, and data science. By focusing on sustainable biochemicals and biological remediation methods, the company aims to transform the soil-remediation industry, which is valued at approximately $20 billion annually.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
SRC Biosciences is a science and technology company that develops, commercializes, and maintains stereology systems. The company is headquartered in Tampa, Florida.
ThinkLive! is an interactive strategy for school systems and teachers, after-school programs, foster care centers, and parents. The company was founded in 2018 and is based in Atlanta, Georgia.
SKROOT Laboratory specializes in the development of wireless sensor systems designed for biotherapeutic process developers. The company has created a unique sensor sticker that, when applied to a reactor and paired with a reader, provides a wireless, non-invasive platform capable of continuously measuring critical parameters such as cell concentration, foaming, and temperature in upstream cell vessels and single-use bioreactors. This innovative technology enables operators to closely monitor bioprocesses, significantly reducing the risk of advancing costly conditions and accelerating the time to market for biotherapeutic products.
NovoClade is a synthetic biology company focused on developing environmentally friendly solutions for insect control and invasive species eradication. The company utilizes gene-editing technology to create sterile mosquito populations, aiming to mitigate the spread of diseases carried by these insects. By offering chemical-free pest control alternatives, NovoClade provides clients with innovative formulas that effectively reduce disease transmission without harming the environment. Through their advancements in genetic bio-control, NovoClade addresses critical public health challenges while promoting sustainable practices in pest management.
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.
Bezoar Laboratories focuses on enhancing health for humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products specifically designed to alleviate gastrointestinal issues, including bloating, constipation, and diarrhea. Their offerings are formulated to be free of gluten and dairy, and they maintain a low acidity level to ensure safety and effectiveness for consumers. By addressing these common health concerns, Bezoar Laboratories aims to improve overall well-being and promote healthier living.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
Sasya is a biotech company that produces functional supplements. Its products are applicable across all species including humans, companion animals, and fish.
Iaso Therapeutics develops vaccines to improve human health and cure diseases. The company was founded in 2018 and is based in East Lansing, Michigan.
Ascribe Bioscience develops products that enable farmers to combat crop pathogens without negative impacts on the environment. The company is currently developing a seed treatment product that acts by boosting crops’ natural defenses.
Lygos is a biotechnology company focused on providing sustainable solutions for renewable chemical production. Founded in 2011 and headquartered in Berkeley, California, Lygos engineers microbes to convert sugars into high-value industrial chemicals, emphasizing cost-effectiveness compared to traditional petrochemical processes. By utilizing advanced throughput screening and strain construction techniques, the company rapidly optimizes biological pathways to transform inexpensive and renewable feedstock into valuable chemical products. Lygos aims to replace persistent and often toxic chemicals with cleaner, more efficient alternatives, catering to business-to-business customers and fostering high-performing, sustainable solutions across the chemical industry.
Abalone Bio, Inc. is a biotechnology company focused on developing antibody drugs for various medical conditions, including pain, inflammatory diseases, rare cancers, and rare kidney diseases. Founded in 2017 and based in Richmond, California, the company aims to create treatments for peripheral neuropathy. Abalone Bio employs advanced techniques such as yeast cell libraries to generate billions of antibody variants, which can either activate or inhibit specific drug targets. Additionally, the company utilizes gene sequencing, machine learning, and synthetic biology to produce recombinant protein versions of its antibodies and to validate their efficacy through human cell assays. This innovative approach allows Abalone Bio to address rare diseases with distinct mechanisms of action.
Sanguine Biosciences, Inc. provides customizable specimen collection services across the United States, maintaining a biorepository of frozen samples from donors with various disease conditions. The company specializes in same-day collection and shipment of time-sensitive blood samples, ensuring that patient samples meet specific study requirements, including demographics and medical history. Sanguine supports clinical and pharmacogenomic studies by offering comprehensive biomaterials storage, sample collection with preferred anticoagulants, and the ability to aliquot samples into suitable volumes. The company collaborates with numerous U.S.-based clinics and hospitals for longitudinal studies and also offers products online. Founded in 2010 and located in Sherman Oaks, California, Sanguine utilizes innovative technology solutions to facilitate clinical trials, including participant recruitment and at-home data collection, thereby aiding clinicians in prescribing appropriate treatments.
Isolere Bio is a biotechnology company dedicated to simplifying the purification processes for biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to these critical drugs, the company is developing innovative technology that utilizes a straightforward Tangential Flow Filtration (TFF) setup. This approach is designed to facilitate a seamless transition from laboratory-scale to industrial-scale production, thereby addressing the growing demand for effective biotherapeutics in research and diagnostics. Through its focus on streamlining bioprocessing, Isolere Bio aims to contribute significantly to advancements in the biopharmaceutical industry.
Soil Culture Solutions, LLC is an agricultural company based in Tampa, Florida, founded in 2014. The company specializes in developing innovative genetic alteration tools aimed at enhancing agricultural productivity and sustainability. By focusing on advanced biotechnological approaches, Soil Culture Solutions seeks to improve crop resilience and efficiency, contributing to the broader goals of modern agriculture.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Pow.bio provides intelligent fermentation services for industrial and synthetic biology, helping turn great ideas into profitable products. We combine continuous fermentation with advanced control methodology to quickly optimize your fermentation process and deliver high yields at low costs. Our scale runs from 1-100 liter capacity for bacteria, yeast, and filamentous fungi.
Cybele Microbiome offers a proprietary platform creates natural products in 16X less time than conventional manufacturing. The company was founded by Nicole Scott in 2017 and it is based in San Diego, California.
NanoView Biosciences is a biotechnology company based in Boston, Massachusetts, specializing in the characterization of extracellular vesicles, particularly exosomes. Utilizing its proprietary ExoView technology, the company provides high-throughput, cost-effective analysis solutions that facilitate the detection and multiparametric characterization of exosomes from complex biological samples such as whole blood, serum, plasma, and urine. NanoView Biosciences offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as custom assays and sample services. The company's innovations support research and the advancement of precision medicine, enabling life science researchers to gain insights into the biological roles of exosomes as potential biomarkers for disease diagnosis, treatment, and monitoring. Founded in 2015, NanoView Biosciences is committed to enhancing the understanding of exosomes in the context of health and disease.
Provider of end-to-end molecular surveillance services intended to treat infectious disease dynamics and molecular surveillance of pathogens. The company's services include ribonucleic acid (RNA) and deoxyribonucleic acid (RNA) extraction, genomic sequencing, data analytics, and cloud-based data visualizations., enabling clients to research and develop various tests and avail of proper lab services.
Developer of biological laboratory instruments designed to make common biological research tasks simple. The company's instruments include a multiwell plate reader whose unprecedentedly small size allows it to work in small labs, enabling researchers to expand their abilities to characterize microbes exponentially.
Developer of life science platform intended to provide accurate methods to test dangerous endotoxins. The company provides advanced healthcare innovations for the detection of blood-borne pathogens, enabling physicians to develop a rapid and sensitive diagnostic for detecting bloodstream infection.
Genoverde Biosciences develops cell wall technology to improve lignocellulosic energy crops and produce liquid fuels from plant sugars. The company was founded in 2015 and is headquartered in Raleigh, North Carolina.
Klar Scientific is a manufacturer specializing in spectroscopic microscopy through its patented confocal optical profile technology. The company produces the Klar Mini Pro microscope, which is a compact and affordable instrument tailored for researchers requiring spectral information with high spatial resolution. This microscope utilizes a laser to focus on samples, while a spectrometer collects the emitted light, allowing research laboratories to achieve clear visualizations through optical adjustments and magnification. Klar Scientific's innovations aim to enhance the capabilities of scientists in various research applications.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Nanopore Diagnostics, LLC specializes in the development of rapid and portable diagnostic products aimed at identifying bacterial infections. The company's flagship product, the iNDxer, is a nanopore sensor designed to count low concentrations of nucleic acid biomarkers in minimally processed samples. This technology allows for the detection of RNA markers specific to pathogenic bacteria, enabling healthcare providers to make informed antibiotic decisions while reducing unnecessary healthcare costs. By facilitating microbiology lab-quality testing at the point of care, Nanopore Diagnostics ensures that physicians have accurate information about the infections they are treating. Founded in 2011 and located in St. Louis, Missouri, the company focuses on enhancing diagnostic capabilities in clinical settings.
Operator of a biotech company intended to provide a diagnostic system for infectious, sexually transmitted diseases and cancer. The company's platform owns an advanced single molecule detection technology and works on the development of non-invasive and ultra-sensing devices and instruments with a specific focus on biomarkers, enabling patients to take diagnostic tests at affordable costs.